Receipt of hematopoietic cell transplantation (HCT) can improve overall survival in older patients with intermediate or highrisk acute myeloid leukemia (AML); however, utilization of HCT is poor. It is important to understand the factors that affect the receipt of HCT in a real-world setting among the older patients. We utilized the National Cancer Database to determine receipt of HCT in older patients (61-75 years) with intermediate or high-risk AML reported between 2003 and 2012. Multivariate logistic regression analysis was used to determine factors associated with receipt of HCT. Only 5.5% of older patients (n = 17,555) underwent HCT. Factors associated with a lower likelihood of receiving HCT included receipt of care in a non-academic hospital, race other than white, older age, Charlson comorbidity score of ≥1, uninsured status, Medicaid or Medicare insurance, and lower educational status. The receipt of HCT in older patients is low and varies based on biological as well as non-biologic factors, such as hospital type, insurance, and educational status. Nationwide efforts to improve access to HCT for appropriate patients are necessary.
Introduction
Timely receipt of allogeneic hematopoietic cell transplant (HCT) can improve overall survival (OS) in acute myeloid leukemia (AML) [1] . Although OS is poor even in older patients with good-risk AML [2] , the role of HCT may be particularly important in those with intermediate or highrisk AML, who have poor prognosis with chemotherapy alone [3, 4] . However, high-non-relapse mortality (NRM) in older patients, who frequently have significant comorbidities and poor functional status, may limit the use of particularly myeloablative HCT [5] . Additionally, a scarcity of high-quality comparative trials demonstrating the value of HCT in older patients may limit the enthusiasm of many oncologists to utilize HCT in older patients. In more recent years, however, studies have clearly demonstrated the feasibility of and exciting results with reduced intensity and non-myeloablative HCT in select older patients including those above the age of 70 years [4, [6] [7] [8] [9] [10] [11] [12] [13] (reviewed by Wall et al. [14] ). A recent analysis from the Center for International Blood and Marrow Transplant Research demonstrated the safety of HCT specifically in patients older than 70 years; survival had increased over the past decade [13] . Some of the prior studies have also highlighted a lack of correlation between NRM and age [7, 8] . Consequently, the current National Comprehensive Cancer Network (NCCN) guideline on AML recommends the use of HCT in first remission in fit older patients with available donor [15] .
Studies have demonstrated a low rate of utilization of HCT in general [16] and in older patients in particular [17, 18] . For example, two US Surveillance, Epidemiology, and End Results (SEER)-Medicare studies demonstrated the use of HCT in <1% of all older AML patients >65 years [17, 18] . Although patients aged >60 years constitute more than half of all AML patients, older patients constitute only 17% of those offered HCT [19] . Besides biological factors, other socioeconomic and health system factors may influence the receipt of HCT. In a nationwide survey of hematologists and medical oncologists in the United States, insurance coverage, age, social support, comorbidity, and race were considered strong determinants of physician referral for HCT [20] . However, factors that are associated with the actual receipt of HCT in older patients have not been studied well. It is important to understand the factors that affect the receipt of HCT in a real-world setting among the older patients. Hence, we utilized data from the National Cancer Data Base (NCDB) to analyze various socioeconomic and health system factors that could influence the receipt of HCT among the older patients with AML.
Methods

Data source and patient selection
We utilized the NCDB participant user file to extract patient-level data of older patients with AML aged ≥61 years who were diagnosed between the time periods of 2003-2012. NCDB is a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. NCDB captures~70% of new cancer diagnosis from >1500 accredited cancer programs in the United States. Data are collected and submitted by certified tumor registrars using standard data item and coding definitions [21] . The institutional review board at the University of Nebraska Medical Center determined that the project does not require IRB approval because of the use of de-identified data.
NCDB provides information on the following variables: patient demographics, socioeconomic status, comorbidity score, tumor characteristics, first course of therapy (but not specifics of chemotherapy), receipt of HCT and facility type. The NCDB provided records of 49,657 older patients with newly diagnosed AML. Patients with good-risk AML (i.e., acute promyelocytic leukemia and core-binding factor AML) were identified using the International Classification of Diseases for Oncology version 3 (ICD-O-3) codes and specific genetic abnormalities. The cohort selection is described in the CONSORT diagram (Supplementary Figure 1) . Patients aged >75 years, good-risk AML, patients with missing data on HCT status and those who did not receive chemotherapy were excluded. To allow an assessment of impact of facility type on the utilization of HCT, patients treated outside of the reporting facility were also excluded.
Study endpoints and variables analyzed
The primary objective of this study was to determine several factors associated with the receipt of HCT in older patients with AML. Subtypes of AML included in this study are listed in Table 1 .
Potential explanatory variables included year of diagnosis, sex, age, race, education, income, distance traveled for health care, hospital type, facility location (urban or rural), geographic region of the facilities, insurance, Charlson comorbidity score, and time from diagnosis to initial therapy initiation ( Table 2 ). The Commission on Cancer categorizes treatment facility type based on program structure, services provided, and the number of cases accessioned each year [22] . For the purpose of this study, facilities were classified into academic centers and nonacademic centers. Academic centers included those with postgraduate medical education in at least four program areas and NCI-designated cancer centers. Non-academic centers included comprehensive community cancer programs, community cancer programs, and other facilities. Educational status is calculated based on the aggregate percent of population without a high school degree residing in the zip code of the patient, as determined by census data of the year 2000. Income status is also derived based on the census data available for the zip code of the patient. The distance between the center of the patient's zip code of residence and the street address of the reporting hospital is used to determine travel distance to the treatment facility. Charlson Comorbidity Score reflects the burden of comorbidities and is divided into three groups with 0, 1, or ≥2 score [23] . 
Statistical analysis
For the univariate analysis, descriptive statistics of frequency and percentage were reported for all predictors stratified by HCT status. NCDB's data use agreement mandates that cell sizes <10 should be suppressed, hence uninsured and unknown insurance status were combined in Table 2 . The χ 2 -test was used to study the association between HCT status and all predictors. A multivariate logistic regression model was used to study the association between HCT status and all predictors simultaneously. Two-way interactions for all predictors were involved in the model, and backward selection was used to determine the final model. Hosmer and Lemeshow Goodness-of-Fit Test was used to assess the goodness-of-fit of the final model. The final model demonstrated a good calibration (Hosmer and Lemeshow Goodness-of-Fit Test, χ 2 -value = 4.40, p = 0.820). Odds ratio (OR) and 95% confidence interval (CI) were presented for the variables in the final model. A p-value <0.05 was considered statistically significant. All analyses were carried out with SAS 9.4 (SAS Institute, Cary, NC, USA) software.
Results
A total of 17,555 older patients were included in the study after exclusion of those with acute promyelocytic leukemia and good-risk AML (Table 1) . Of all the studied patients, only 5.5% (n = 959) underwent allogeneic or autologous HCT (Supplementary Table 1 ). The median age of the study population was 68 years (range 61-75 years). The study population consisted of predominantly white (88%), male (58%), and those with Charlson comorbidity score of 0 (70%) or 1 (22%). Patients frequently received treatment in an urban location (98%) and an academic center (56%).
In a univariate analysis, younger age, lower Charlson comorbidity score, white versus African Americans or other racial groups, receipt of first course treatment in an academic center, higher educational, income, and insurance status were associated with a higher likelihood of receiving HCT (Table 2) . Importantly, the receipt of HCT was higher in patients with private and other government insurance. More recent years of diagnosis, certain geographic regions, longer distance traveled by patients, and longer time to initiation of initial therapy also were associated with a higher probability of receiving HCT. A multivariate analysis demonstrated a lower likelihood of receiving HCT among patients treated at non-academic centers (p = 0.0002) or certain geographic regions (p = 0.0002), in African Americans (p = 0.003) and other racial group (p = 0.0005), uninsured (p = 0.0003), Medicaid (p < 0.0001), and Medicare patients (p < 0.0001) ( Table 3 ). Other factors associated with a lower receipt of HCT were lower educational status, older age, and higher Charlson comorbidity score. Patients, who traveled ≥37 miles to receive care, and those receiving initial therapy after 14 days of diagnosis or in the more recent calendar years (2007 and later) were more likely to receive HCT. Only the interaction of facility type by geographic region was significant. The effect of the facility type on utilization of HCT was determined to be different for different geographic regions, and the effect of geographic region on the utilization of HCT was also different for different facility types.
Discussion
The utilization of HCT in older patients with AML, albeit slowly improving in more recent years, was low in this NCDB study. The results are consistent with SEERMedicare studies [17, 18] . Although lower in non-academic Indicates the p-value for the two-way interaction centers, the use of upfront HCT was low even in patients treated at academic centers. A low utilization of HCT in our study may partly be related to a lack of randomized trials demonstrating OS benefit with HCT in older patients. Some older patients may prefer not to undergo HCT, have significant comorbidities, not achieve remission or develop chemotherapy-related toxicities precluding them from HCT. This is consistent with our finding of a lower receipt of HCT in patients older than 70 years and those with higher Charlson comorbidity score. However, Fred Hutchinson Cancer Research Center and the University of Washington have demonstrated that more than one-third of newly diagnosed patients with intermediate or high-risk AML aged ≤75 years can receive an allogeneic HCT [24] . A Netherlands' population-based study also demonstrated that approximately half of AML patients younger than 60 years, and 17% of patients between 61 and 70 years received allogeneic HCT in 2007-2012 [25] . Hence, additional socioeconomic and health system factors are likely to explain a lower utilization of HCT in this study.
In this context, our multivariate analysis demonstrated a many-fold lower use of HCT in patients receiving therapy at non-academic centers, highlighting a significant role of health system factors in determining the receipt of HCT. Additionally, racial groups other than whites, and patients with lower educational status were less likely to undergo HCT. Insurance status was also strongly correlated with the likelihood of receiving HCT. Uninsured patients, as well as Medicare/Medicaid patients were much less likely to receive HCT than private insurers, consistent with a prior report [26] . These racial and educational factors can impact the receipt of HCT in many ways. First, the availability of matched unrelated donors is lower in non-whites, which provides a biological link between race and a lower rate of receipt of HCT. Second, racial and educational factors may influence the perception and understanding of the risk-benefit of HCT. Third, racial and educational factors may influence social support or access to the transplant center. Fourth, physicians may base their referral practices on such factors [20] . Health care disparity in the receipt of care based on racial and educational factors is concerning.
Patients who traveled ≥37 miles to receive care and those receiving initial therapy after 14 days had a higher likelihood of undergoing HCT. The reason is not entirely clear. We speculate that longer distance to the treating facility may indicate better functional status of the patients or receipt of care in academic centers; however, the interaction between academic status of facility and travel distance was not observed in our study. Patients who could delay therapy for more than 2 weeks may presumably have less aggressive or more favorable disease biology that allowed them to proceed to HCT without early disease progression. We did not have data on the distance to the closest transplant center, although this consideration may disproportionately affect certain patients and explain why patients who travel >37 miles for leukemia care may also be more likely to get a transplant.
Our study is limited by its retrospective design, missing information on functional status and lack of understanding of the reasons patients did not receive HCT. Some patients especially those who lack strong social support may prefer to avoid the use of HCT. Data on marital status or social support system and patient preferences are not captured in this database. These limitations prevent understanding of the exact reasons for not receiving HCT and reduce our ability to accurately quantify the impact of factors noted to have association with receipt of HCT in our study. Additionally, some differences in the comparison groups are small albeit statistically significant. Despite such limitations, this large database study highlights a number of non-biological factors associated with the receipt of HCT in a real-world practice. The low receipt of HCT in older patients and the presence of disparity in the utilization of HCT based on hospital type, race, insurance, and educational status will require nationwide efforts to improve access to HCT. Timely referral of potentially eligible patients to a transplant center, adoption of alternate donor transplant strategies at various transplant centers, strengthening partnership between transplant centers and referring oncologists, multidisciplinary approach to management of patient's physical and mental comorbidities, and concerted efforts to educate patients and referring oncologists are some of the potential strategies to increase the use of HCT.
